We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COX-2 Inhibitors Slow Bone Growth and Impede Healing

By Biotechdaily staff writers
Posted on 04 Dec 2002
Researchers working with a rabbit model have found that selective COX-2 inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex) interfere with the healing process after a bone fracture or cementless joint implant surgery. These findings were published in the November 2002 issue of the Journal of Orthopedic Research.

"It is very common. You break a bone and go to the ER. The doctor sets it in a splint and prescribes one of these anti-inflammatory drugs (including COX-2 inhibitors) for pain,” said first author Dr. Stuart Goodman, MD, professor of orthopedic surgery at the Stanford School of Medicine (Stanford, CA, USA). "We now know that could actually delay healing.”

The investigators implanted a titanium device called a harvest chamber into the tibia bone of eight New Zealand white rabbits. The device has a removable, hollow inner core that allows periodic removal of the tissue growing inside. The growth of new bone into the chamber simulates healing of a fracture or joint implant. The rabbits were given oral treatments of naproxen (a nonspecific COX inhibitor) or rofecoxib separated by four weeks without treatment. After each treatment, the harvest chamber's core was removed and the tissue growing inside extracted and examined under the microscope using special stains, including monoclonal antibodies.

Since the harvest chamber allows new tissue to be extracted multiple times as it grows back, the rabbits served as their own control groups (after consuming plain water). The researchers found that while the tissue in the control group contained 24.8% and 29.9% new bone growth, the tissue harvested after the rabbits consumed naproxen and rofecoxib contained significantly less: 15.9% and 18.5%, respectively. As the difference in new bone growth associated with the two drugs was statistically insignificant, the COX-2 inhibitor impeded new bone growth as much as the nonspecific NSAID.

Dr. Goodman said this study "has great applicability to humans, because the healing process is virtually the same” for rabbit and human bones.



Related Links:
Stanford University

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
04 Dec 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
04 Dec 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
04 Dec 2002  |   BioResearch